Wilson Sonsini Goodrich & Rosati and Shanghai-headquartered Fangda Partners have advised WuXi Biologics, a Chinese contract drug research and development company, on its $511 million initial public offering in Hong Kong. Maples and Calder represented WuXi as well, serving as its Cayman Islands counsel.

Shearman & Sterling and China’s Jingtian & Gongcheng were also involved in the IPO, representing underwriters Bank of America Merrill Lynch, Morgan Stanley and China Merchant Securities. 

This IPO is Hong Kong's largest new listing so far in 2017, reported Reuters.

WuXi Biologics is the second Chinese company to relist in Hong Kong after going private in the U.S. Its parent company, WuXi PharmaTech, was delisted from the U.S. in December 2015 through a $3.3 billion management buyout.  

The Shearman team included partners Colin Law, Paloma Wang, Matthew Bersani and Laurence Crouch. The Maples team was led by partner Derrick Kan.